BRINTELLIX (vortioxetine), antidepressant
PSYCHIATRY - New medicinal product
Opinions on drugs -
Posted on
Jun 08 2015
Reason for request
Inclusion
No clinical benefit demonstrated in the treatment of major depressive episodes by comparison with other antidepressants
-
BRINTELLIX has Marketing Authorisation in the treatment of major depressive episodes in adults.
-
It is a new alternative to the antidepressants that are currently available. The clinical data (superiority studies versus placebo and non-inferiority study versus comparator) did not demonstrate superiority over the available alternatives.
Clinical Benefit
| Moderate |
- |
Clinical Added Value
| no clinical added value |
- |
English version
Contact Us
Évaluation des médicaments
